𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Sequential chemotherapy in nonsmall-cell lung cancer : Cisplatin and gemcitabine followed by docetaxel

✍ Scribed by Anna Ceribelli; Maria S. Pino; Alain J. Gelibter; Michele Milella; Fabiana L. Cecere; Mauro Caterino; Francesco Facciolo; Alessandra Mirri; Francesco Cognetti

Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
72 KB
Volume
109
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

BACKGROUND.

Improving results in nonsmall‐cell lung cancer (NSCLC) will require the development of new drugs and strategies to combine available agents. On the basis of data indicating the activity of docetaxel as second‐line therapy, a Phase II study was conducted to evaluate the efficacy and toxicity of the sequential combination of chemotherapy consisting of cisplatin (P) and gemcitabine (G) followed by docetaxel (DOC) in patients with advanced NSCLC.

METHODS.

Patients with 1997 TNM stage IIIB (pleural effusion)/stage IV NSCLC, performance status (PS) of 0–1, and normal organ function were eligible. Therapy consisted of P at 75 mg/m^2^ on Day 1 and G 1200 mg/m^2^ on Days 1 and 8 every 3 weeks for 3 cycles followed, in nonprogressive patients, by DOC 30 mg/m^2^ every week for 6 consecutive weeks every 8 weeks for 2 cycles.

RESULTS.

Fifty‐two eligible patients were enrolled (M/F, 39/13; stage IIIB/IV, 8/44; PS 0, 73%, PS 1, 27%; median age, 58 years; range, 36–73). The overall response rate was 36.5% (95% confidence interval [CI]: 23–49). The median overall survival was 11 months (95% CI: 9–13); the median progression‐free survival was 6 months (95% CI: 5–7); and the 1‐ and 2‐year survivals were 48% and 25%, respectively. One‐ and 2‐year progression‐free survivals were 12% and 8%, respectively. Both phases of the treatment protocol were well tolerated.

CONCLUSIONS.

P/G followed by weekly DOC is well tolerated and active as first‐line therapy for NSCLC patients and provides a feasible chemotherapeutic option in this clinical setting. Cancer 2007 © 2007 American Cancer Society.

📜 SIMILAR VOLUMES

Sequential combination chemotherapy in p
Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma : Carboplatin and gemcitabine followed by paclitaxel
✍ Martin J. Edelman; David R. Gandara; Derrick H. M. Lau; Primo Lara; I. Jun Laude 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB 👁 2 views

## Background: The objective of this phase ii study was to evaluate the concept of sequential chemotherapy in the treatment of patients with advanced nonsmall cell lung carcinoma (nsclc) by the administration of carboplatin plus gemcitabine followed by of paclitaxel. ## Methods: Patients with sta

A phase I-II study of docetaxel-ifosfami
A phase I-II study of docetaxel-ifosfamide-cisplatin (DIP) combination chemotherapy regimen in advanced nonsmall cell lung cancer
✍ Christos Kosmas; Nicolas B. Tsavaris; Thomas Makatsoris; Adimchi Onyenadum; Mari 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 French ⚖ 96 KB 👁 1 views

## Abstract In an attempt to develop more effective chemotherapy regimens in advanced nonsmall cell lung cancer (NSCLC), we evaluated docetaxel‐ifosfamide‐cisplatin (DIP) based on our previous experience with paclitaxel‐ifosfamide‐cisplatin. Patients with advanced NSCLC (stages III‐IV), WHO‐PS≤2, n

A Phase II trial of gemcitabine and doce
A Phase II trial of gemcitabine and docetaxel in patients with chemotherapy-naive, advanced nonsmall cell lung carcinoma
✍ Irina E. Popa; Kathleen Stewart; Frederick P. Smith; Naiyer A. Rizvi 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB 👁 2 views

## Abstract ## BACKGROUND The goals of the current study were to determine the safety and efficacy of a nonplatinum‐containing doublet, gemcitabine and docetaxel, in the treatment of patients with chemotherapy‐naive nonsmall cell lung carcinoma (NSCLC). ## METHODS Thirty‐two patients with advanc